Anti-SRP-54 and Anti-Ro-52 Antibodies: Clinical Associations

Introduction to Autoantibody Associations

The American College of Rheumatology suggests that anti-SRP antibodies are primarily associated with necrotizing myopathy characterized by acute onset, severe proximal muscle weakness, markedly elevated muscle enzymes, dilated cardiomyopathy, and poor response to standard immunosuppression in patients with inflammatory myopathies 1, 2
The European League Against Rheumatism recommends measuring anti-SRP antibodies when evaluating suspected inflammatory myopathies, as they are myositis-specific autoantibodies that target a 6-polypeptide complex 1, 2

The presence of anti-SRP antibodies is associated with necrotizing myopathy, markedly elevated muscle enzymes, and cardiac involvement, including dilated cardiomyopathy, in approximately 5-10% of adult inflammatory myopathy patients and 1-3% of juvenile dermatomyositis cases 1, 3
The American Thoracic Society suggests that anti-Ro-52 antibodies should be measured when evaluating suspected Sjögren's syndrome, overlap myositis features, newly detected interstitial lung disease of unknown cause, and juvenile dermatomyositis with overlap features 4, 5

The American College of Rheumatology recommends that the presence of anti-Ro-52 in connective tissue diseases should prompt aggressive evaluation for interstitial lung disease, including pulmonary function tests and high-resolution CT scanning, due to its association with worse outcomes and survival 4, 5
The European Respiratory Society notes that anti-Ro-52 antibodies are strongly associated with interstitial lung disease in connective tissue diseases, with a sensitivity of 96.2% and specificity of 83.3% for detecting ILD 4

The American College of Rheumatology notes that anti-SRP antibodies target a 6-polypeptide complex and are found in approximately 5-10% of adult patients with idiopathic inflammatory myopathies 6
The European League Against Rheumatism acknowledges that the hallmark features of anti-SRP antibodies include necrotizing myopathy with acute onset and severe proximal muscle weakness 6
The American Heart Association recognizes that anti-SRP antibodies are associated with dilated cardiomyopathy and cardiac disease 6

The American Thoracic Society states that anti-SRP antibodies are associated with interstitial lung disease (ILD), though this is not the primary or most characteristic manifestation of anti-SRP myopathy 6
The Mayo Clinic finds that anti-SRP antibodies are not among the primary myositis-specific antibodies strongly associated with ILD, unlike the antisynthetase antibodies (anti-Jo-1, PL-7, PL-12, etc.) which are the hallmark of antisynthetase syndrome with ILD as a cardinal feature 6

The American College of Cardiology recommends prioritizing cardiac evaluation given the strong association with dilated cardiomyopathy 6
The European Respiratory Society suggests that the presence of ILD may indicate worse prognosis and require more aggressive immunosuppression, although this is not directly cited, the poor response to standard immunosuppression is noted 6